search
Back to results

Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation

Primary Purpose

Diarrhea, Constipation

Status
Completed
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
probiotics (antibiophilus(Lactobacillus casei), bio-three)
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diarrhea focused on measuring probiotics

Eligibility Criteria

3 Months - 10 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Diarrhea
  • constipation

Exclusion Criteria:

  • Shock
  • Sepsis
  • Past history with GI tract surgery
  • Immunodeficiency

Sites / Locations

  • Chang Gung Memorial Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

97-0549B

Arm Description

Outcomes

Primary Outcome Measures

Duration of diarrhea, number of stool passage, bacterial culture for intestinal or cytokine

Secondary Outcome Measures

body weight change, appetite and daily intake, Fecal IgA, lactoferrin and calprotectin levels
secondary outcome including body weight change, appetite and daily intake, bloating or abdominal distension, abdominal pain or colic, constipation, fever, and vomiting were also assessed. IgA levels and bacterial culture were performed on homogenized fecal samples. Fecal lactoferrin and calprotectin levels were measured with samples of feces.

Full Information

First Posted
September 23, 2008
Last Updated
July 16, 2012
Sponsor
Chang Gung Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00763399
Brief Title
Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation
Official Title
Phase 4 Study of Probiotics on Intestinal Bacterial Population and Immune Modulation
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
October 2008 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chang Gung Memorial Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The balance between immunogenic and tolerogenic activities in human immune system strongly depends on microflora-induced pro-and anti-inflammatory activities. Probiotics are important components of microflora. The interactions of the different strains of probiotics and the cells of immune system are largely unknown. There are many mechanisms by which probiotics enhance intestinal health, including stimulation of immunity, competition for limited nutrients, inhibition of epithelial and mucosal adherence, inhibition of epithelial invasion and production of antimicrobial substances. Fecal immunoglobulin A(IgA), lactoferrin and calprotectin were determined by enzyme-linked immunosorbent assay(ELISA) and compared in different groups. Other clinical symptoms or signs, including fever, vomiting, diarrhea, abdominal pain, bloating abdomen, daily intake and body weight were also assessed. The first aim of our study is to evaluate the role of probiotics and their preparation products on the restoration of intestinal bacterial population. The second aim of our study is determining the immunomodulating effects or anti-inflammatory effects of probiotics on the host (human being). We try to seek to gain an advanced understanding of probiotics versus intestinal microorganism and host interactions, as well as mucosal immune responses to probiotics in the intestine.
Detailed Description
Some clinical parameters were evaluated according to the following: primary outcome (severity of diarrhea), and secondary outcome including body weight change, appetite and daily intake, bloating or abdominal distension, abdominal pain or colic, constipation, fever, and vomiting were also assessed. Peripheral blood isolated by Lymphoprep, washed twice in normal saline and once in medium, and suspended in medium [RPMI 1640] to a density of 1 x 106/mL. PBMCs will be isolated from blood donor buffy coats by density gradient centrifugation. The concentration of PBMCs will be adjusted to 106 cells per ml in complete medium, and the cells will be transferred to 24-well plates.Cell surface phenotype expression and intracellular staining. Cells will be stained using a panel of monoclonal antibody (MAb) directed against surface antigens expressed by lymphocytes, monocytes and the appropriate species-specific immunoglobulin G isotype controls. Cells will be acquired using an FACScan (Becton Dickinson) and analyzed with Cell Quest software. To assess the colonization of intestinal bacteria, fecal samples were collected from each patient on day 0 (the day when patients were enrolled), day 3 and day 7 after probiotics or placebo treatment. The fecal specimens were weighed, homogenized, and serially diluted and plated on selective agar for analysis of bacteria. Fecal bacteria count was expressed as log10 CFU/g feces. Fecal samples were collected during the treatment period. IgA levels were performed on homogenized fecal samples. Total IgA was determined using goat anti-human IgA-HRP conjugate. The reaction was developed with tetramethyl benzidine (TMB; Zymed Labs.) and read at 450 nm. OD values were converted to ng/g feces of total IgA by comparison with a standard curve developed with anti-human IgA. The stool samples were prepared and analyzed for lactoferrin. A polyclonal antibody specific for lactoferrin has been pre-coated onto a microplate. Lactoferrin in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for lactoferrin, which is recognized by a streptavidin-peroxidase conjugate. Absorbance is read at OD 450 nm. Lactoferrin was expressed as μg/g feces. The stool samples were prepared and analyzed for calprotectin. The supernatant was collected and frozen at -20°C. The supernatants were thawed and calprotectin was analyzed with the quantitative calprotectin ELISA and read at OD 450 nm. Calprotectin was expressed as μg/g feces.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea, Constipation
Keywords
probiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
97-0549B
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
probiotics (antibiophilus(Lactobacillus casei), bio-three)
Intervention Description
probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10^8CFU/day
Primary Outcome Measure Information:
Title
Duration of diarrhea, number of stool passage, bacterial culture for intestinal or cytokine
Time Frame
within 4 weeks
Secondary Outcome Measure Information:
Title
body weight change, appetite and daily intake, Fecal IgA, lactoferrin and calprotectin levels
Description
secondary outcome including body weight change, appetite and daily intake, bloating or abdominal distension, abdominal pain or colic, constipation, fever, and vomiting were also assessed. IgA levels and bacterial culture were performed on homogenized fecal samples. Fecal lactoferrin and calprotectin levels were measured with samples of feces.
Time Frame
Within first two weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Diarrhea constipation Exclusion Criteria: Shock Sepsis Past history with GI tract surgery Immunodeficiency
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chien-Chang Chen, MD
Organizational Affiliation
Pediatric Department, Chang Gung Memorial Hospital, Taiwan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation

We'll reach out to this number within 24 hrs